Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.
Approval Alert | Intravesical Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
2
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
3
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
4
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
5
